<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905137</url>
  </required_header>
  <id_info>
    <org_study_id>015-2013</org_study_id>
    <nct_id>NCT01905137</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain</brief_title>
  <official_title>Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Urogynecology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Urogynecology Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there is a change in patient-reported&#xD;
      pelvic pain following pelvic floor injections of 200 units of Botox compared with 20cc of&#xD;
      normal saline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      Primary objective: To evaluate the change in patient-reported pelvic pain following pelvic&#xD;
      floor injections of 200 units of Botox compared with 20cc of normal saline.&#xD;
&#xD;
      Secondary objective: To evaluate the change in patient-reported pelvic pain following Botox&#xD;
      injections in conjunction with pelvic floor physical therapy compared to saline injections&#xD;
      with physical therapy.&#xD;
&#xD;
      Hypothesis We hypothesize that women in the Botox treatment arm, compared with those in the&#xD;
      saline arm, will have a greater decrease in patient-reported pain on palpation of their most&#xD;
      painful levator ani muscle group at two weeks after the injection.&#xD;
&#xD;
      To test this hypothesis we will measure patient-reported pain on palpation of each levator&#xD;
      ani muscle group at baseline and two weeks following the injection. Pain will be assessed on&#xD;
      a 10-point visual analog scale. We will compare the baseline and two-week pain measurements&#xD;
      for the most painful muscle group.&#xD;
&#xD;
      We hypothesize that with the addition of physical therapy, women in the Botox treatment arm,&#xD;
      compared with those in the saline arm, have a greater decrease in patient-reported pain on&#xD;
      palpation of their most painful levator ani muscle group at 12 weeks after the injection.&#xD;
&#xD;
      To test this hypothesis we will measure patient-reported pain on palpation of each levator&#xD;
      ani muscle group at baseline and 12 weeks following the injection. Pain will be assessed on a&#xD;
      10-point visual analog scale. We will compare the baseline and 12-week pain measurements for&#xD;
      the most painful muscle group.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      All patients will be screened for eligibility during their routine office visit. If they meet&#xD;
      all eligibility criteria, they will be offered enrollment. At this visit, all patients will&#xD;
      be counseled about conservative treatment options for dealing with irritative voiding&#xD;
      symptoms, bowel symptoms, and pain. The counseling offered will be standardized for all&#xD;
      patients. After patients are consented, they will undergo an initial evaluation with a pelvic&#xD;
      floor physical therapist. Patients will then return for an office visit to receive their&#xD;
      treatment. The patients will be pretreated with 100mg of topical Lidocaine hydrochloride&#xD;
      jelly, 2%, in the vagina for 15 minutes prior to their injections. A designated medical&#xD;
      assistant will open an opaque sealed envelope to determine whether the patient is randomized&#xD;
      to the Botox or saline arm. The medical assistant will draw up the appropriate&#xD;
      solution-either 20mL of saline or 200 units of Botox A diluted in preservative-free saline,&#xD;
      to achieve a concentration of 10 units per mL. Both the Botox and saline will be drawn into 2&#xD;
      unlabeled 10mL syringes in order to ensure the physician remains blinded to treatment arm&#xD;
      assignment. The saline or Botox will be injected to the coccygeus, piriformis, obturator&#xD;
      internus, puborectalis, iliococcygeus, and pubococcygeus muscles bilaterally for a total of&#xD;
      1-2mL per muscle group. Using digital vaginal palpation, the muscles to be injected will be&#xD;
      located with care taken to locate tender and contracted points on the muscle fibers. The&#xD;
      index finger is used for palpation as the 20-gauge pudendal block needle with the guide is&#xD;
      advanced to the target site piercing through the vaginal mucosa to the intended muscle&#xD;
      groups. The needle is placed into the intended muscles under direct palpation for injection&#xD;
      of 1-2mL aliquots.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      This is a double-blinded, randomized controlled trial. Participants will be randomized to&#xD;
      either Botox or saline in a ratio of 1:1 using computer-generated block randomization. The&#xD;
      statistician will create the sequentially numbered opaque sealed envelopes to conceal group&#xD;
      assignment.Study visits Baseline visit Once determined eligible, patients will be offered&#xD;
      enrollment into the study. After consent forms are signed, we will obtain study data.&#xD;
      Participants will then see a physical therapist at a designated pelvic floor physical therapy&#xD;
      center to evaluate their pelvic floor prior to any intervention.&#xD;
&#xD;
      Injection visit Following the pelvic floor physical therapy assessment, participants will&#xD;
      return to the urogynecology office for their injection of saline or Botox as specified above.&#xD;
&#xD;
      Two-week post-injection visit At two weeks, patients will return for outcome assessments.&#xD;
      Four-week post-injection visit Patients will return at 4 weeks for the same outcome&#xD;
      assessment they had at 2 weeks. After the 4-week visit, participants will start pelvic floor&#xD;
      physical therapy. They will go to physical therapy for a total of 8 sessions, done as close&#xD;
      to weekly as possible.&#xD;
&#xD;
      Twelve-week post-injection visit At 12 weeks patients will return for outcome assessments.&#xD;
      After all outcome data are collected, the provider and the patient will be unblinded.&#xD;
      Patients who were randomized to the placebo group will be offered 200 Units of Botox&#xD;
      injection at no cost. These 32 patients will be encouraged to continue with weekly physical&#xD;
      therapy for 8 weeks following the Botox injection. We will ask these participants to return&#xD;
      at 2 weeks and 12 weeks after the injection for outcome assessments. During these visits we&#xD;
      will collect the same data as for the 2-week and 12-week visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Actual">March 9, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the change in patient-reported pelvic pain following pelvic floor injections of 200 units of Botox compared with 20cc of normal saline.</measure>
    <time_frame>2 weeks after pelvic floor injection</time_frame>
    <description>To test this hypothesis we will measure patient-reported pain on palpation of each levator ani muscle group at baseline and two weeks following the injection. Pain will be assessed on a 10-point visual analog scale. We will compare the baseline and two-week pain measurements for the most painful muscle group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change in patient-reported pelvic pain following Botox injections in conjunction with pelvic floor physical therapy compared to saline injections with physical therapy.</measure>
    <time_frame>12 weeks following pelvic floor injection</time_frame>
    <description>To test this we will measure patient-reported pain on palpation of each levator ani muscle group at baseline and 12 weeks following the injection. Pain will be assessed on a 10-point visual analog scale. We will compare the baseline and 12-week pain measurements for the most painful muscle group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Myofascial Pelvic Pain</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the treatment group will receive 200 Units of Botulinum toxin diluted in 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the placebo group will receive 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention-Botulinum Toxin Type A</intervention_name>
    <description>Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.</description>
    <arm_group_label>Botulinum Toxin Type A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Saline</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than 18&#xD;
&#xD;
          -  Diagnosis of myofascial pain by an attending urogynecologist&#xD;
&#xD;
          -  Persistent pelvic pain present for â‰¥50% of days over the past 3 months at a level of 6&#xD;
             or greater on a 10-point visual analog scale&#xD;
&#xD;
          -  On physical exam, a short, tight pelvic floor with pain on palpation of at least 6 on&#xD;
             a 10-point visual analog scale in at least one muscle group (coccygeus, pyriformis,&#xD;
             obturator internus, iliococcygeus, puborectalis, or pubococcygeus).&#xD;
&#xD;
          -  Ability to read English, provide written, informed consent and be able and willing to&#xD;
             go to pelvic floor physical therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Any of the following a pre-existing neurologic or neuromuscular condition that&#xD;
             precludes them from Botox injections, such as myasthenia gravis, a bleeding disorder;&#xD;
             or sensitivity or allergy to Botox&#xD;
&#xD;
          -  Current use of aminoglycosides or any other medication that may potentiate the&#xD;
             neuromuscular weakness that could be caused by concomitant use of Botox also will be&#xD;
             ineligible&#xD;
&#xD;
          -  History of treatment with Botox to the pelvic floor&#xD;
&#xD;
          -  Presence of any masses or lesions on physical exam&#xD;
&#xD;
          -  Pelvic organ prolapse greater than stage 2&#xD;
&#xD;
          -  Plan for pelvic floor surgery or pelvic floor physical therapy treatment in the next&#xD;
             three months&#xD;
&#xD;
          -  Change in pain medication usage in the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eman A Elkadry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Auburn Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Urogynecology Associates</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Urogynecology Associates</investigator_affiliation>
    <investigator_full_name>Sybil Dessie, MD</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <keyword>Myofascial pelvic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

